Overview
- Commave will acquire Zevra’s serdexmethylphenidate portfolio, including AZSTARYS and KP1077, for $50 million.
- The purchase agreement includes a mutual settlement of Commave’s 2024 Delaware Chancery Court litigation against Zevra.
- Zevra repaid the principal on its $63 million term loan before the agreement, leaving the company debt‑free.
- Company leadership frames the move as a shift toward core rare‑disease programs, including its U.S.-marketed therapy for Niemann‑Pick disease type C.
- ZVRA shares traded about 4.6% higher at $10.44 following the news, according to Benzinga.